The role of FAPI PET/CT in patients with lymphoma: a systematic review.

Frontiers in nuclear medicine (Lausanne, Switzerland) Pub Date : 2025-05-09 eCollection Date: 2025-01-01 DOI:10.3389/fnume.2025.1589903

Natale Quartuccio, Stefania Nicolosi, Sabina Pulizzi, Dante D'Oppido, Salvatore Ialuna

{"title":"The role of FAPI PET/CT in patients with lymphoma: a systematic review.","authors":"Natale Quartuccio, Stefania Nicolosi, Sabina Pulizzi, Dante D'Oppido, Salvatore Ialuna","doi":"10.3389/fnume.2025.1589903","DOIUrl":null,"url":null,"abstract":"Introduction: Fluorodeoxyglucose (FDG) PET/CT is typically the reference imaging method for assessing and tracking lymphomas. However, fibroblast activation protein inhibitor (FAPI) PET is being explored as a potentially useful option, especially when Fluorodeoxyglucose (FDG) scans do not show clear results.Methods: For this systematic review, two researchers searched PubMed/MEDLINE and Cochrane CENTRAL for studies on FAPI PET/CT in lymphoma patients.Results: The literature search initially retrieved 249 articles. After removing duplicates and screening titles and abstracts, and full text, there was a final selection of 15 articles (3 original studies and 12 case reports), encompassing a total of 270 patients. The three original studies were judged to have a low risk of bias according to the QUADAS-2 criteria. The systematic review reveals that FAPI PET/CT exhibits lower diagnostic sensitivity than [18F]FDG PET/CT in lymphomas characterized by low FAP expression. Nevertheless, FAPI PET/CT retains potential as a complementary imaging modality.Discussion: [18F]FDG PET/CT remains the gold standard in lymphoma imaging, but FAPI PET/CT can potentially provide supplementary information regarding the molecular characteristics of lymphomas. FAPI PET/CT may have prognostic and therapeutic implications. In particular, it could help identify lymphoma subgroups with distinct stromal environments, potentially serving as a prognostic biomarker. Further large-scale prospective studies are warranted to validate its role in lymphoma management.","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"5 ","pages":"1589903"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101064/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in nuclear medicine (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fnume.2025.1589903","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Fluorodeoxyglucose (FDG) PET/CT is typically the reference imaging method for assessing and tracking lymphomas. However, fibroblast activation protein inhibitor (FAPI) PET is being explored as a potentially useful option, especially when Fluorodeoxyglucose (FDG) scans do not show clear results.

Methods: For this systematic review, two researchers searched PubMed/MEDLINE and Cochrane CENTRAL for studies on FAPI PET/CT in lymphoma patients.

Results: The literature search initially retrieved 249 articles. After removing duplicates and screening titles and abstracts, and full text, there was a final selection of 15 articles (3 original studies and 12 case reports), encompassing a total of 270 patients. The three original studies were judged to have a low risk of bias according to the QUADAS-2 criteria. The systematic review reveals that FAPI PET/CT exhibits lower diagnostic sensitivity than [¹⁸F]FDG PET/CT in lymphomas characterized by low FAP expression. Nevertheless, FAPI PET/CT retains potential as a complementary imaging modality.

Discussion: [¹⁸F]FDG PET/CT remains the gold standard in lymphoma imaging, but FAPI PET/CT can potentially provide supplementary information regarding the molecular characteristics of lymphomas. FAPI PET/CT may have prognostic and therapeutic implications. In particular, it could help identify lymphoma subgroups with distinct stromal environments, potentially serving as a prognostic biomarker. Further large-scale prospective studies are warranted to validate its role in lymphoma management.

查看原文本刊更多论文

FAPI PET/CT在淋巴瘤患者中的作用：一项系统综述。

简介：氟脱氧葡萄糖（FDG） PET/CT通常是评估和跟踪淋巴瘤的参考成像方法。然而，成纤维细胞活化蛋白抑制剂（FAPI） PET作为一种潜在的有用选择正在被探索，特别是当氟脱氧葡萄糖（FDG）扫描没有显示明确的结果时。方法：两名研究人员在PubMed/MEDLINE和Cochrane CENTRAL检索FAPI PET/CT在淋巴瘤患者中的研究。结果：文献检索最初检索到249篇。在去除重复、筛选标题、摘要和全文后，最终选择了15篇文章（3篇原创研究和12篇病例报告），共包括270名患者。根据QUADAS-2标准，三个原始研究被判定为低偏倚风险。系统综述显示，FAPI PET/CT对以FAP低表达为特征的淋巴瘤的诊断敏感性低于[18F]FDG PET/CT。尽管如此，FAPI PET/CT仍有潜力作为一种补充成像方式。讨论：[18F]FDG PET/CT仍然是淋巴瘤成像的金标准，但FAPI PET/CT可以潜在地提供有关淋巴瘤分子特征的补充信息。FAPI PET/CT可能具有预后和治疗意义。特别是，它可以帮助识别具有不同基质环境的淋巴瘤亚群，可能作为预后生物标志物。需要进一步的大规模前瞻性研究来验证其在淋巴瘤治疗中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in nuclear medicine (Lausanne, Switzerland)

CiteScore

0.90

自引率

0.00%

发文量